[1] [1] O. V. Semyachkina-Glushkovskaya, A. S. Abdurashitov, E. I. Saranceva, E. G. Borisova, A. A. Shirokov, N. V. Navolokin, “Blood-brain barrier and laser technology for drug brain delivery," J. Innov. Opt. Health Sci. 5, 10 (2017).

[2] [2] M. Ferrari, “Cancer nanotechnology: Opportunities and challenges," Nat. Rev. Cancer 5, 161–171 (2005).

[3] [3] G. Kaul, M. Amiji, “Biodistribution and targeting potential of poly (ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model," J. Drug Target. 12, 585–591 (2004).

[4] [4] G. Kaul, M. Amiji, “Tumor-targeted gene delivery using poly (ethylene glycol)-modified gelatin nanoparticles: In vitro and in vivo studies," Pharm Res. 22, 951–961 (2005).

[5] [5] A. K. Cherian, A. C. Rana, S. K. Jain, “Selfassembled carbohydrate stabilized ceramic nanoparticles for the parenteral delivery of insulin," Drug DevInd Pharm. 26, 459–463 (2000).

[6] [6] S. K. Sahoo, V. Labhasetwar, “Nanotech approaches to drug delivery and imaging," Drug Discov Today. 8, 1112–1120 (2003).

[7] [7] V. P. Torchilin, “Targeted polymeric micelles for delivery of poorly soluble drugs," Cell. Mol. Life. Sci. 61, 2549–2559 (2004).

[8] [8] J. E. Chung, S. Tan, S. J. Gao, N. Yongvongsoontorn, S. H. Kim, J. H. Lee, H. S. Choi, H. Yano, L. Zhuo, M. Kurisawa, J. Y. Ying, “Self-assembled micellarnanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy," Nat. Nanotechnol. 208, 907 (2014).

[9] [9] J. Thawonsuwan, V. Kiron, S. Satoh, A. Panigrahi, V. Verlhac, “Epigallocatechin-3-gallate (EGCG) affects the antioxidant and immune defense of the rainbow trout, Oncorhynchusmykiss," Fish PhysiolBiochem. 36, 687–697 (2010).

[10] [10] C. Chi, S. Guoxiang, V. Hebbar, “Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells," Carcinogensis 24, 1369–1378 (2003).

[11] [11] A. Mittal, M. S. Pate, R. C. Wylie, T. O. Tollefsbol, S. K. Katiyar, “EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis," Int. J. Oncol. 24, 703–710 (2004).

[12] [12] X.-P. Liu, X.-L. Wen, S.-N. Zou, “Induction of apoptosis by epigallocatechin-3-gallate via activating mitochondrial signaling in human gastric cancer cells," J. Nanhua Univ. 4, 499–502 (2007).

[13] [13] Z. Fang, D. Cheng, “EGCG inhibited the proliferation of liver canner HepG2 cells through NF-κBpathway," Chin. J. Gastroenterol. Hepatol. 3, 229–231 (2012).

[14] [14] L. Chen, M. J. Lee, H. Li, C. S. Yang, “Absorption, distribution, elimination of tea polyphenols in rats," Drug Metab. Dispos. Biol. Fate Chem. 25, 1045–1050 (1997).

[15] [15] S. Sang, J. D. Lambert, C. S. Yang, “Bioavailability and stability issues in understanding the cancer preventive effects of tea polyphenols," J. Sci. Food Agric. 86, 2256–2265 (2006).

[16] [16] A. Dube, K. Ng, J. A. Nicolazzo, I. Larson, “Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution," Food Chem. 122(3), 662–667 (2010).

[17] [17] K. A. Janes, M. P. Fresneau, A. Marazuela, A. Fabra, M. J. Alonso, “Chitosan nanoparticles as delivery systems for doxorubicin," J. Control. Release. 73, 255–267 (2001).

[18] [18] S. Mitra, U. Gaur, P. C. Ghosh, “Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier," Control. Release. 74, 317–323 (2001).

[19] [19] C. Yang, R. Hu, T. Anderson, Y. Wang, G. Lin, W.-C. Law, W.-J. Lin, Q. T. Nguyen, H. T. Toh, H. S. Yoon, C.-K. Chen, K.-T. Yong, “Biodegradable nanoparticle-mediated K-ras down regulation for pancreatic cancer gene therapy," J. Mater. Chem. B. 3, 2163–2172 (2015).

[20] [20] K. A. Janes, M. P. Fresneau, A. Marazuela, A. Fabra, M. J. Alonso, “Chitosan nanoparticles as delivery systems for doxorubicin," J. Control. Release. 73, 255–267 (2001).

[21] [21] Y. Pan, Y. J. Li, H. Y. Zhao, J. M. Zheng, H. Xu, G. Wei, J. S. Hao, F. D. Cui, “Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo," Int. J. Pharm. 249, 139 (2002).

[22] [22] Q.-F. He, G.-M. Li, H.-Z. Wu, Z.-M. Lu, L. Li, “Preparation and drug releasing property of 5-fluorouracil-loaded chitosan microsphere," Chin. J. Appl. Chem. 21, 192–196 (2004).

[23] [23] D. G. Kim, Y. I. Jeong, C. Choi, S. H. Roh, S. K. Kang, M. K. Jang, J. W. Nah, “Retinol-encapsulated low molecular water-soluble chitosan nanoparticles," Int. J. Pharmaceutics 319, 130 (2006).

[24] [24] Y. Cho, J. T. Kim, H. J. Park, “Size-controlled selfaggregated N-acyl chitosan nanoparticles as a vitamin C carrier," Carbohydr. Polym. 88, 1087–1092 (2012).

[25] [25] J. Liang, L. Cao, L. Zhang, X.-C. Wan, “Preparation, characterization, and in vitro antitumor activity of folate conjugated chitosan coated EGCG nanoparticles," Food Sci. Biotechnol. 23, 569–575 (2014).

[26] [26] F. Lei, X. Wang, C. Liang, F. Yuan, Y. Gao, “Preparation and functional evaluation of chitosan-GCG conjugates," J. Appl. Polym. Sci. 131, 39732 (2014).

[27] [27] J. Ouyang, Z. Xia, P. Lu, “Application of TEM and SAED on inorganic nano-materials," J. Jinan Univ. 33, 87–93 (2012).